用于三叉神经痛治疗的新型Transform支架的台式与体外实验
本研究开发了用于三叉神经痛(TN)治疗的新型Transform支架,并与Enterprise支架进行台式力学性能与体外血液相容性对比。结果显示Transform支架在直径1.0 mm及以上血管中径向力更高、神经血管模型中的跟踪性更好、弯曲刚度更强,而Enterprise支架的贴壁性更优;体外血液相容性试验未观察到显著血栓形成问题。作者认为Transform支架是潜在选择,为未来TN的血管内治疗研究奠定基础。
要点
- Transform支架在直径1.0 mm及以上血管中径向力高于Enterprise支架。
- Transform支架在神经血管模型中的跟踪性优于Enterprise支架。
- Transform支架弯曲刚度更强,Enterprise支架贴壁性更优;体外血液相容性试验未观察到显著血栓形成问题。
核心结论
- 本研究显示Transform支架是潜在选择,为未来三叉神经痛治疗的创新血管内方法铺平道路。
- 台式与体外评价所显示的Transform支架特性可作为体内预实验和临床研究的第一步。
研究设计与样本
- 台式与体外实验研究,比较Transform支架与Enterprise支架用于三叉神经痛治疗的表现。
- 两种支架均为自膨胀闭孔设计、由镍钛合金管经激光切割制成,且仅Enterprise支架在颅内动脉置入的安全性有临床报道。
- 每个支架模型的径向力、跟踪性、弯曲刚度和贴壁性等台式测量均重复三次,并报告平均值。
主要发现
- 在直径1.0 mm及以上的血管中,Transform支架的径向力高于Enterprise支架。
- 在神经血管模型中,Transform支架的跟踪性优于Enterprise支架。
- Transform支架的弯曲刚度更强,而Enterprise支架的贴壁性更优。
- 体外血液相容性试验未观察到显著血栓形成问题。
临床怎么用
- 作者认为Transform支架是潜在选择,为未来三叉神经痛的创新血管内治疗铺平道路。
- 作者指出台式与体外评价所确认的Transform支架特性可作为体内预实验和临床研究的第一步。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trigeminal neuralgia (TN) is a debilitating condition characterized by sudden, excruciating facial pain due to neurovascular compression of the trigeminal nerve. Stent deployment can change the course of the superior cerebellar artery upwards, possibly releasing the root entry zone of the trigeminal nerve. We developed a novel stent, the Transform stent, for TN treatment, and evaluated its mechanical properties using benchtop and in vitro hemocompatibility tests. METHODS: We compared the performance of Transform and Enterprise stents in treating TN because they share similar self-expanding closed-cell features in the manufacturing process, are derived from nitinol tubes, and are fabricated through a laser-cutting process, but also because only the safety of Enterprise stents deployed in intracranial arteries has been reported clinically. All benchtop measurements, including radial force, trackability, bending stiffness, and conformability, were performed thrice for each stent model, and their average values are presented. RESULTS: Transform stents showed higher radial forces in vessels of diameters ranging from 1.0 mm than Enterprise stents. The trackability of the Transform stent was better than that of the Enterprise stent in a neurovascular model. Bending stiffness was stronger in the Transform stent whereas conformability was superior in the Enterprise stent. No significant thrombogenic issues were observed in the in vitro hemocompatibility tests. CONCLUSIONS: This study demonstrated the Transform stent as a potential option and paved the way for innovative endovascular approaches for the future TN treatment. Namely, the study confirmed that the characteristics of Transform stents at benchtop and in vitro evaluations may be used as a first step for studies such as in vivo pre- and clinical studies.
引用
- Kim J, Kim H, Park CH, et al. Benchtop and in Vitro Experiments of Novel Transform Stents for Trigeminal Neuralgia Treatment. World Neurosurg. 2024. PMID: 38522785. doi:10.1016/j.wneu.2024.03.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。